ValuEngine lowered shares of Insys Therapeutics (NASDAQ:INSY) from a strong-buy rating to a buy rating in a report released on Wednesday.
INSY has been the subject of a number of other reports. Zacks Investment Research upgraded Insys Therapeutics from a sell rating to a hold rating in a research note on Thursday, October 11th. Jefferies Financial Group reiterated a buy rating and issued a $10.00 price target on shares of Insys Therapeutics in a research note on Friday, August 10th. Piper Jaffray Companies set a $4.00 price target on Insys Therapeutics and gave the company a sell rating in a research note on Saturday, August 11th. Finally, Royal Bank of Canada reiterated a buy rating and issued a $9.00 price target on shares of Insys Therapeutics in a research note on Thursday, August 9th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock has an average rating of Hold and a consensus price target of $7.67.
Insys Therapeutics stock opened at $6.71 on Wednesday. Insys Therapeutics has a one year low of $5.04 and a one year high of $14.00. The stock has a market capitalization of $487.95 million, a price-to-earnings ratio of -13.69 and a beta of 1.67.
Several large investors have recently made changes to their positions in the company. Bridgeway Capital Management Inc. raised its stake in shares of Insys Therapeutics by 11.2% in the third quarter. Bridgeway Capital Management Inc. now owns 84,700 shares of the specialty pharmaceutical company’s stock worth $854,000 after purchasing an additional 8,500 shares during the last quarter. BNP Paribas Arbitrage SA raised its stake in shares of Insys Therapeutics by 47.4% in the second quarter. BNP Paribas Arbitrage SA now owns 31,105 shares of the specialty pharmaceutical company’s stock worth $225,000 after purchasing an additional 10,001 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Insys Therapeutics in the third quarter worth about $113,000. Creative Planning purchased a new position in shares of Insys Therapeutics in the third quarter worth about $153,000. Finally, Tower Research Capital LLC TRC purchased a new position in shares of Insys Therapeutics in the second quarter worth about $131,000. Hedge funds and other institutional investors own 18.45% of the company’s stock.
About Insys Therapeutics
Insys Therapeutics, Inc, a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS.
Further Reading: Systematic Risk and Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Insys Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.